We’re taking aim at chronic disease and we won’t give up until we conquer.

Biospherics, a wholly owned subsidiary of Spherix Incorporated, is a leader in the application of chiral carbohydrate chemistry and research in the metabolic syndrome.  The Company’s new lead candidate is SPX-106T, a therapeutic combination licensed from the college of pharmacy for reducing triglycerides, cholesterol and atherosclerosis.  Biospherics also has phase 3 clinical trial results with D-tagatose, a naturally occurring, simple sugar being developed as an oral treatment for glycemic control in patients with Type 2 diabetes.  For more on treatment of these diseases, see the preclinical pipeline.